Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NY-ESO-1 TCR - Kite Pharma

Next Previous
X
Search
Drug Profile

NY-ESO-1 TCR - Kite Pharma

Alternative Names: anti-NY-ESO-1 TCR

Latest Information Update: 31 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Developer Kite Pharma; National Cancer Institute (USA); Takara Bio
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours
  • Phase I/II Soft tissue sarcoma

Most Recent Events

  • 03 Dec 2019 Takara Bio suspends phase I/II trial in Soft tissue sarcoma (In children, In adolescents, In adults, In the elderly, Metastatic disease, Second-line therapy or greater, Combination therapy) in Japan (IV) (JMA-IIA00346)
  • 01 Dec 2019 Phase-I/II clinical trials in Soft tissue sarcoma (In children, In adolescents, In adults, In the elderly, Metastatic disease, Second-line therapy or greater, Combination therapy) in Japan (IV) before December 2019 (JMA-IIA00346)
  • 24 Jun 2019 Phase-II development is ongoing USA (NCT01967823)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top